Compare NEO & BSTZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NEO | BSTZ |
|---|---|---|
| Founded | 2001 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Precision Instruments | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.6B |
| IPO Year | 2008 | N/A |
| Metric | NEO | BSTZ |
|---|---|---|
| Price | $9.91 | $23.17 |
| Analyst Decision | Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $11.50 | N/A |
| AVG Volume (30 Days) | ★ 1.7M | 194.2K |
| Earning Date | 05-18-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 8.31% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.71 |
| Revenue | N/A | N/A |
| Revenue This Year | $10.53 | N/A |
| Revenue Next Year | $9.25 | N/A |
| P/E Ratio | ★ N/A | $32.69 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.72 | $15.22 |
| 52 Week High | $13.74 | $23.47 |
| Indicator | NEO | BSTZ |
|---|---|---|
| Relative Strength Index (RSI) | 29.37 | 53.87 |
| Support Level | $9.28 | $22.70 |
| Resistance Level | $11.65 | $23.19 |
| Average True Range (ATR) | 0.66 | 0.48 |
| MACD | -0.20 | 0.04 |
| Stochastic Oscillator | 23.86 | 74.12 |
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. It operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.
BlackRock Science and Technology Trust II is a non-diversified, closed-end management investment company. The trust's investment objectives are to provide total return and income through a combination of current income, current gains, and long-term capital appreciation. Its portfolio consists of Equity Securities, Options, Preferred Securities, Convertible Securities, Depositary Receipts, Non-U.S. Securities, Emerging Markets Investments, Restricted and Illiquid Investments, Private Company Investments, Corporate Bonds, and other investments. The trust seeks to Invest at least 80% of its total assets in equity securities issued by U.S. and non-U.S. science and technology companies in any market capitalization range from the development, advancement, and use of science and/or technology.